Search

Displaying results 1071 - 1080 of 10000 in total
  1. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  2. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    [A274391] Dordaviprone has several modes of action, including the activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription … Factor 4 (ATF4), and induction of endoplasmic reticulum (ER) stress response.

    Synonyms: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one, 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-one
  3. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.

  4. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    ), another tyrosine kinase inhibitor used as a first-line treatment for CML. … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec

  5. Drug

    Dobutamine

    go.drugbank.com/drugs/DB00841
    ApprovedInvestigational

    A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

    Mixtures: Dobutamine Hydrochloride in DextroseCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Methyl nicotinate

    go.drugbank.com/drugs/DB13882
    Approved

    Methyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain.

  7. Drug

    Bedaquiline

    go.drugbank.com/drugs/DB08903
    ApprovedInvestigational

    [A261856] Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] … [A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market.

  8. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778] … Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.

  9. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    It is found in foods for food enrichment or in supplements for the treatment of iron deficiency or iron deficiency anemia.

    Mixtures: Triveen-Duo DHA, SetonET-EC
  10. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting